โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT06164587RECRUITINGIRB Ready

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

(K8 for GA)

Sponsored by University of Kentucky

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...
๐Ÿ“Š
1 of 30 participants interested
3% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30.

Who Can Participate

Inclusion Criteria

Aged 50 or older, diagnosed with geographic atrophy (GA) due to age-related macular degeneration (AMD).
Best corrected visual acuity (BCVA) 24 or greater Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (approximately Snellen 20/320 or greater), in study eye.
The entire geographic atrophy (GA) lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy except in such cases where there is a "neck" or some narrow area connecting the GA with the peripapillary atrophy, as determined by Fundus Autofluorescence (FAF) imaging at screening:
Both eyes must have GA and the total GA area in each eye must be โ‰ฅ 2.5 and โ‰ค 20.0 mm2 (1 and 8 disk areas \[DA\] respectively)
If geographic atrophy (GA) is multifocal, at least one focal lesion must be โ‰ฅ 1.25 mm2 (0.5 DA), with the overall aggregate area of GA, as specified above.
If geographic atrophy

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

30 participants

๐ŸŽ‚

Age Range

50 Years - 99 Years

โšง

Gender

ALL

๐Ÿข

Sponsor

University of Kentucky

Study Locations

Choose your preferred location or select flexible during enrollment

Unknown

Loma Linda

California

Location available
View Loma Linda location page
Unknown

Lexington

Kentucky

Location available
View Lexington location page
Unknown

Portland

Maine

Location available
View Portland location page
Unknown

Eugene

Oregon

Location available
View Eugene location page
Unknown

Hilton Head

South Carolina

Location available
View Hilton Head location page
Unknown

Sioux Falls

South Dakota

Location available
View Sioux Falls location page
Unknown

Hixson

Tennessee

Location available
View Hixson location page
Unknown

Bristol

Virginia

Location available
View Bristol location page
Unknown

Roanoke

Virginia

Location available
View Roanoke location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Looking for Geographic Atrophy Treatment in Loma Linda?

Join others in California exploring innovative treatment options through clinical research

Geographic Atrophy Treatment Options in Loma Linda, California

If you're searching for Geographic Atrophy treatment in Loma Linda, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Loma Linda, Lexington, Portland and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Geographic Atrophy. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 30 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Geographic Atrophy?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Geographic Atrophy

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Geographic Atrophy Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06164587. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.